EXHIBITS AND FINANCIAL STATEMENT SCHEDULE

12 Months Ended

Dec. 31, 2023

SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]

Exhibits and Financial Statement Schedule

(a)(1) Financial Statements

The information required by this Item is included in Item 8 of Part II of this Form 10-K.

(a)(2) Financial Statement Schedule

The following financial statement schedule for the years ended December 31, 2023, 2022 and 2021, is included in this Form 10-K as set forth below (in thousands).

Pediatrix Medical Group, Inc.

Schedule II: Valuation and Qualifying Accounts

	Years Ended December 31,
	2023			2022			2021
Allowance for contractual adjustments and uncollectibles:
Balance at beginning of year	$	1,251,705		$	1,091,310		$	791,842
Amount charged against operating revenue		6,069,245			5,921,519			5,436,786
Accounts receivable contractual adjustments and write-offs    (net of recoveries)		(6,214,050	)		(5,761,124	)		(5,137,318	)
Balance at end of year	$	1,106,900		$	1,251,705		$	1,091,310

All other schedules have been omitted because they are not applicable, not required or the information is included elsewhere herein.

(a)(3) Exhibits

See Item 15(b) of this Form 10-K.